z-logo
Premium
Four PTEN ‐targeting co‐expressed mi RNA s and ACTN 4‐ targeting mi R ‐548b are independent prognostic biomarkers in human squamous cell carcinoma of the oral tongue
Author(s) -
Berania Ilyes,
Cardin Guillaume B.,
Clément Isabelle,
Guertin Louis,
Ayad Tareck,
Bissada Eric,
NguyenTan Phuc Felix,
Filion Edith,
Guilmette Julie,
Gologan Olguta,
Soulieres Denis,
Rodier Francis,
Wong Philip,
Christopoulos Apostolos
Publication year - 2017
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.30915
Subject(s) - pten , microrna , cancer research , biology , gene , cancer , oncology , medicine , genetics , signal transduction , pi3k/akt/mtor pathway
The purpose of this study was to determine the prognostic value and oncogenic pathways associated to miRNA expression in squamous cell carcinoma of the oral tongue and to link these miRNA candidates with potential gene targets. We performed a miRNA screening within our institutional cohort ( n  = 58 patients) and reported five prognostic targets including a cluster of four co‐expressed miRNAs (miR‐18a, miR‐92a, miR‐103, and miR‐205). Multivariate analysis showed that expression of miR‐548b ( p  = 0.007) and miR‐18a ( p  = 0.004, representative of co‐expressed miRNAs) are independent prognostic markers for squamous cell carcinoma of the oral tongue. These findings were validated in The Cancer Genome Atlas (TCGA) cohort ( n  = 131) for both miRNAs (miR‐548b: p  = 0.027; miR‐18a: p  = 0.001). Bioinformatics analysis identified PTEN and ACTN4 as direct targets of the four co‐expressed miRNAs and miR‐548b, respectively. Correlations between the five identified miRNAs and their respective targeted genes were validated in the two merged cohorts and were concordantly significant (miR‐18a/PTEN: p  < 0.0001; miR‐92a/PTEN: p  = 0.0008; miR‐103/PTEN: p  = 0.008; miR‐203/PTEN: p  = 0.019; miR‐548b/ACTN4: p  = 0.009).

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here